FDA Releases Final Risk Evaluation and Mitigation Strategies (REMS) for Extended Release/Long Acting Opioids Including a Prescriber Education Program Read more
FDA REMS: Blue Print for Prescriber Continuing Education Program for Extended Release-Long Acting Opioids Read more